Status:
COMPLETED
The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Prostate Cancer Metastatic Disease
PET / CT
Eligibility:
MALE
Brief Summary
Investigators retrospectively collected data from consecutive patients treated at the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, from October 2020 to March 2024. The inclusio...
Eligibility Criteria
Inclusion
- patients with diagnosis of metastatic hormone-sensitive prostate cancer, confirmed by PSA levels, radiographic tests and pathological information
- patients who underwent FDG and PSMA PET/CT prior to the initiation of medical treatment
Exclusion
- patients who received novel hormone therapy or a prostate biopsy prior to PET/CT
- patients with other malignancies
- patients received hormone therapy without novel hormone therapy
- patients received chemotherapy or radiotherapy prior to or during novel hormone therapy
- absence of follow-up data at our institution
Key Trial Info
Start Date :
June 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2025
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06915714
Start Date
June 2 2024
End Date
February 28 2025
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First affiliated hospital, Sun Yat-sen univeristy
Guangzhou, Guangdong, China, 510080